Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Market

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension that is characterized by the elevated pulmonary arterial pressure and pulmonary vascular resistance in blood vessels carrying the blood from the right side of the heart through lungs. 

It occurs due to the tightening and stiffening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction.


The disease is found to be more common among women as compared to men. It is also observed that patients with Systemic Sclerosis, Sickle Cell Disease, and Human Immunodeficiency Virus infection (HIV infection) are at a higher risk of developing Pulmonary Arterial Hypertension (PAH).


Pulmonary Arterial Hypertension Epidemiological Segmentation 

The Epidemiological Segmentation of Pulmonary Arterial Hypertension in 7MM from 2017 to 2030 is segmented as:- 

  • Prevalent Population of Pulmonary Arterial Hypertension  
  • Subtype-Specific Prevalent Population of Pulmonary Arterial Hypertension
  • Gender-Specific Prevalent Population of Pulmonary Arterial Hypertension 


Pulmonary Arterial Hypertension Epidemiology 

  • Women are more affected by PAH as compared to men.
  • Pulmonary Arterial Hypertension prevalence among the population older than 65 years was 451 per million individuals. 
  • Total prevalent cases of Pulmonary Arterial Hypertension in 7MM in 2017 was 70,774 


Pulmonary Arterial Hypertension Market

The Market Size of Pulmonary Arterial Hypertension in the 7MM in 2017 was USD 4.6 Billion 


Pulmonary Arterial Hypertension Market Drivers

  • Increasing prevalence of Pulmonary Arterial Hypertension
  • Increasing government support for developing drugs for PAH
  • Numerous late-stage ongoing clinical trials 


Pulmonary Arterial Hypertension Emerging Drugs

The emerging drugs of the Pulmonary Arterial Hypertension market are 

  • Aurora-GT 
  • Ralinepag 
  • RVT-1201 
  • Sotatercept 
  • Bardoxolone methyl 
  • Inhaled dry powder treprostinil 
  • PB1046 Injection 
  • CXA-10 

And many others. 


Pulmonary Arterial Hypertension Key Players

The key players in the Pulmonary Arterial Hypertension market are

  • United Therapeutics Corp
  • Arena Pharmaceuticals
  • Altavant Sciences
  • Acceleron Pharma, Inc
  • Reata Pharmaceuticals, Inc
  • Liquidia Technologies, Inc
  • PhaseBio PharmaceuticalsInc
  • Complexa, Inc.

And many others.